Skip to main content
Premium Trial:

Request an Annual Quote

FDA Asks Correlogic Systems for a Meeting on Marketing of its Ovarian Cancer Test

NEW YORK, Feb. 25 (GenomeWeb News) - Steve Gutman, the director of the US Food and Drug Administration's Office of In Vitro  Diagnostic Device Evaluation and Safety, has asked Correlogic Systems to discuss the marketing of the company's test for predicting ovarian cancer, GenomeWeb News  has learned.

 

In the letter to company president Peter Levine, which is dated Feb. 18, Gutman said the test is a device and may be subject to the agency's premarket review requirements.


The test, called OvaCheck, was developed by Correlogic and scientists at the National Cancer Institute and the FDA, and is licensed to clinical lab giants Quest Diagnostics and LabCorp.

 

Correlogic executives were unavailable for immediate comment, the company said.


Click here  to view a copy of the letter, which is posted on the FDA website.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.